news – Page 195

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Clinical Updates Diabetes & Endocrinology news Specialties

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY 09/07/2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.

Clinical Updates Diabetes & Endocrinology news

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

By MedXY 09/07/2025

Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.

Dermatology Infectious Diseases news

One Dose or Three? Reevaluating Benzathine Penicillin G Therapy for Early Syphilis

By MedXY 09/07/2025

A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.

Cardiology news Specialties

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

By MedXY 09/07/2025

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Clinical Updates Diabetes & Endocrinology news Specialties

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY 09/07/2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

Critical Care news Specialties

Top Ten Essential Tips for Palliative Care Clinicians Consulting in Intensive Care Units

By MedXY 09/07/2025

This article provides ten practical tips for palliative care clinicians to optimize consultation effectiveness in ICUs, emphasizing collaboration, communication, cultural respect, conflict resolution, and transition planning to improve patient and family outcomes.

Clinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY 09/07/2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.

Allergy & Immunology Clinical Updates Family Medicine & Nutrition news Specialties

Iron Supplementation and Accelerated Aging: The Inflammatory Link and Dietary Mitigation

By MedXY 09/07/2025

Excessive iron supplementation accelerates phenotypic aging via inflammation, but anti-inflammatory and antioxidant diets may mitigate this risk, highlighting the importance of balanced iron intake and dietary patterns in aging health.

Family Medicine & Nutrition Gastroenterology news Specialties

Linarin as a Multifaceted Therapeutic Agent for NAFLD: Modulation of PI3K/Akt/mTOR, Autophagy, and Gut Microbiota

By MedXY 09/07/2025

Linarin shows promise in mitigating NAFLD by enhancing autophagy via PI3K/Akt/mTOR inhibition, reducing inflammation, and restoring gut microbiota balance, alongside activating the PDE4D/cAMP/PKA/CREB pathway to improve hepatic lipid metabolism and oxidative stress.

Family Medicine & Nutrition news Psychiatry Specialties

Pro-Inflammatory Diets Elevate Risk of Depression and Anxiety: Insights from a Large UK Biobank Study

By MedXY 09/07/2025

A prospective UK Biobank study reveals that diets with higher pro-inflammatory potential, as measured by the Dietary Inflammatory Index, are significantly associated with increased risk of depressive and anxiety symptoms and disorders over 14 years.

Family Medicine & Nutrition Neurology news Specialties

Anti-Inflammatory Diet and Alzheimer’s Disease Mortality: Insights from a National Cohort Study

By MedXY 09/07/2025

Higher adherence to an anti-inflammatory diet is linked to lower all-cause mortality and a trend toward reduced Alzheimer's disease mortality, particularly among men and non-Hispanic Whites, highlighting dietary modification as a potential strategy to mitigate neuroinflammation and AD risk.

Diabetes & Endocrinology news Specialties

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY 09/07/2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

news Pediatrics Psychiatry Specialties

Midazolam Outperforms Melatonin as Premedication for Anxiety in Children Undergoing Elective Surgery: Insights from the MAGIC Trial

By MedXY 09/07/2025

The MAGIC trial reveals midazolam’s superior efficacy over melatonin in reducing preoperative anxiety in children undergoing general anaesthesia, despite melatonin’s favorable safety profile. Challenges in recruitment and implications for future research are discussed.

Cardiology Clinical Updates news Specialties

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

By MedXY 09/07/2025

The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.

Cardiology Clinical Updates news Specialties

Minimizing Anesthesia in Transcatheter Aortic Valve Implantation: Insights from the DOUBLE-CHOICE Trial

By MedXY 09/07/2025

The DOUBLE-CHOICE randomized trial demonstrates non-inferiority of isolated local anesthesia versus conscious sedation in transfemoral TAVI, suggesting a safe minimalist anesthesia strategy with potential trade-offs in patient comfort.

Family Medicine & Nutrition news Specialties

Rethinking the ‘Five a Day’: Why More Fruits and Vegetables Could Mean a Healthier Life

By MedXY 09/07/2025

New research suggests increasing daily fruit and vegetable intake beyond the classic five portions can substantially reduce chronic disease risk and mortality.

Family Medicine & Nutrition news Specialties

Debunking 10 Common Nutrition Myths: Insights from Longevity Experts

By MedXY 09/06/2025

Explore 10 widespread nutrition misconceptions clarified by longevity medicine experts, backed by scientific evidence, to guide healthier dietary choices and improve public understanding.

Cardiology Clinical Updates General Surgery news Specialties

Surgical Management of Left-Sided Infective Endocarditis: Insights from the Nationwide NIDUS Registry

By MedXY 09/06/2025

A nationwide Danish study reveals that while 40% of left-sided infective endocarditis patients have surgical indications, only half undergo surgery. Those receiving surgery are younger, less comorbid, and show improved survival, underscoring the need for refined risk assessment in high-risk cases.

Clinical Updates news Public Health Specialties

The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift

By MedXY 09/06/2025

The US FDA's unprecedented exemption of clinical efficacy studies for a ustekinumab biosimilar marks a transformative regulatory milestone, reshaping biosimilar development, market dynamics, and patient access worldwide.